{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:34:17Z","timestamp":1792978457789,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"DOI":"10.7759\/cureus.99998","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:13:28Z","timestamp":1766578408000},"source":"Crossref","is-referenced-by-count":3,"title":["Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study"],"prefix":"10.7759","author":[{"given":"Seigo","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Kurinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Hieshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar N","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, et al.. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010, 375:2215-22. 10.1016\/S0140-6736(10)60484-9","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph JJ","year":"2022","unstructured":"Joseph JJ, Deedwania P, Acharya T, et al.. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022, 145:e722-59. 10.1161\/CIR.0000000000001040","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.11.043","article-title":"Decreased plasma levels of active glucagon-like peptide-1 in coronary artery disease","volume":"65","author":"Akiyama E","year":"2015","unstructured":"Akiyama E, Sugiyama S, Matsubara J, et al.. Decreased plasma levels of active glucagon-like peptide-1 in coronary artery disease. J Am Coll Cardiol. 2015, 65:754-5. 10.1016\/j.jacc.2014.11.043","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02647-2","article-title":"Correction: glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges","volume":"24","author":"Westermeier F","year":"2025","unstructured":"Westermeier F, Fisman EZ. Correction: glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges. Cardiovasc Diabetol. 2025, 24:118. 10.1186\/s12933-025-02647-2","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/706416","article-title":"Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus","volume":"2015","author":"Jinnouchi H","year":"2015","unstructured":"Jinnouchi H, Sugiyama S, Yoshida A, et al.. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res. 2015, 2015:706416. 10.1155\/2015\/706416","journal-title":"J Diabetes Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019, 394:121-30. 10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli C","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5:251-60. 10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13905","article-title":"Efficacy and safety of once-weekly semaglutide in Japanese individuals with type\u20092 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: post-hoc analysis","volume":"13","author":"Araki E","year":"2022","unstructured":"Araki E, Harashima S, Nishida T, Nakamura J. Efficacy and safety of once-weekly semaglutide in Japanese individuals with type\u20092 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: post-hoc analysis. J Diabetes Investig. 2022, 13:1971-80. 10.1111\/jdi.13905","journal-title":"J Diabetes Investig"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0068","article-title":"Secondary prevention strategy of cardiovascular disease using endothelial function testing","volume":"79","author":"Matsuzawa Y","year":"2015","unstructured":"Matsuzawa Y, Guddeti RR, Kwon TG, Lerman LO, Lerman A. Secondary prevention strategy of cardiovascular disease using endothelial function testing. Circ J. 2015, 79:685-94. 10.1253\/circj.CJ-15-0068","journal-title":"Circ J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000208","article-title":"Predictive value of endothelial function by noninvasive peripheral arterial tonometry for coronary artery disease","volume":"26","author":"Matsuzawa Y","year":"2015","unstructured":"Matsuzawa Y, Li J, Aoki T, et al.. Predictive value of endothelial function by noninvasive peripheral arterial tonometry for coronary artery disease. Coron Artery Dis. 2015, 26:231-8. 10.1097\/MCA.0000000000000208","journal-title":"Coron Artery Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-023-02124-w","article-title":"GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?","volume":"60","author":"Menghini R","year":"2023","unstructured":"Menghini R, Casagrande V, Rizza S, Federici M. GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?. Acta Diabetol. 2023, 60:1441-8. 10.1007\/s00592-023-02124-w","journal-title":"Acta Diabetol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00094-2","article-title":"Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude","volume":"146","author":"Kuvin JT","year":"2003","unstructured":"Kuvin JT, Patel AR, Sliney KA, et al.. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003, 146:168-74. 10.1016\/S0002-8703(03)00094-2","journal-title":"Am Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus","volume":"57","author":"Sugiyama S","year":"2018","unstructured":"Sugiyama S, Jinnouchi H, Kurinami N, et al.. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus. Intern Med. 2018, 57:2147-56. 10.2169\/internalmedicine.0701-17","journal-title":"Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.748574","article-title":"Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study","volume":"117","author":"Hamburg NM","year":"2008","unstructured":"Hamburg NM, Keyes MJ, Larson MG, et al.. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008, 117:2467-74. 10.1161\/CIRCULATIONAHA.107.748574","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"Pharmacologic approaches to glycemic treatment. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S181-206. 10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-12-1168","article-title":"Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes","volume":"77","author":"Matsubara J","year":"2013","unstructured":"Matsubara J, Sugiyama S, Akiyama E, et al.. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013, 77:1337-44. 10.1253\/circj.cj-12-1168","journal-title":"Circ J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.08.062","article-title":"Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia","volume":"44","author":"Bonetti PO","year":"2004","unstructured":"Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004, 44:2137-41. 10.1016\/j.jacc.2004.08.062","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002270","article-title":"Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis","volume":"4","author":"Matsuzawa Y","year":"2015","unstructured":"Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis. J Am Heart Assoc. 2015, 4:e002270. 10.1161\/JAHA.115.002270","journal-title":"J Am Heart Assoc"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi SH","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024, 15:20420188231222367. 10.1177\/20420188231222367","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1669685","article-title":"Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection","volume":"12","author":"Battistoni A","year":"2025","unstructured":"Battistoni A, Piras L, Tartaglia N, Carrano FM, De Vitis C, Barbato E. Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection. Front Med (Lausanne). 2025, 12:1669685. 10.3389\/fmed.2025.1669685","journal-title":"Front Med (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.206425","article-title":"Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A","volume":"30","author":"Oeseburg H","year":"2010","unstructured":"Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillj\u00e9 HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010, 30:1407-14. 10.1161\/ATVBAHA.110.206425","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2011.149","article-title":"Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells","volume":"33","author":"Ding L","year":"2012","unstructured":"Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin. 2012, 33:75-81. 10.1038\/aps.2011.149","journal-title":"Acta Pharmacol Sin"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter J","year":"2020","unstructured":"Helmst\u00e4dter J, Frenis K, Filippou K, et al.. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol. 2020, 40:145-58. 10.1161\/atv.0000615456.97862.30","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6518221","article-title":"The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes","volume":"2021","author":"Yaribeygi H","year":"2021","unstructured":"Yaribeygi H, Farrokhi FR, Abdalla MA, Sathyapalan T, Banach M, Jamialahmadi T, Sahebkar A. The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes. J Diabetes Res. 2021, 2021:6518221. 10.1155\/2021\/6518221","journal-title":"J Diabetes Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in\u00a0ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski G","year":"2018","unstructured":"Rakipovski G, Rolin B, N\u00f8hr J, et al.. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in\u00a0ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018, 3:844-57. 10.1016\/j.jacbts.2018.09.004","journal-title":"JACC Basic Transl Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.03.032","article-title":"Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis","volume":"352","author":"Jensen JK","year":"2022","unstructured":"Jensen JK, Binderup T, Grandjean CE, Bentsen S, Ripa RS, Kjaer A. Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis. 2022, 352:88-95. 10.1016\/j.atherosclerosis.2022.03.032","journal-title":"Atherosclerosis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.athplu.2022.05.004","article-title":"Semaglutide treatment attenuates vessel remodelling in ApoE-\/- mice following vascular injury and blood flow perturbation","volume":"49","author":"Jensen DM","year":"2022","unstructured":"Jensen DM, Skovsted GF, Bonde MF, et al.. Semaglutide treatment attenuates vessel remodelling in ApoE-\/- mice following vascular injury and blood flow perturbation. Atheroscler Plus. 2022, 49:32-41. 10.1016\/j.athplu.2022.05.004","journal-title":"Atheroscler Plus"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.995007","article-title":"Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice","volume":"13","author":"Yue L","year":"2022","unstructured":"Yue L, Chen S, Ren Q, et al.. Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice. Front Endocrinol (Lausanne). 2022, 13:995007. 10.3389\/fendo.2022.995007","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110196","article-title":"Semaglutide alleviates inflammation-Induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes","volume":"119","author":"Pan X","year":"2023","unstructured":"Pan X, Yang L, Wang S, Liu Y, Yue L, Chen S. Semaglutide alleviates inflammation-Induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes. Int Immunopharmacol. 2023, 119:110196. 10.1016\/j.intimp.2023.110196","journal-title":"Int Immunopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/438170-once-weekly-semaglutide-is-associated-with-improvement-in-vascular-endothelial-function-in-patients-with-type-2-diabetes-mellitus-a-retrospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:13:29Z","timestamp":1766578409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/438170-once-weekly-semaglutide-is-associated-with-improvement-in-vascular-endothelial-function-in-patients-with-type-2-diabetes-mellitus-a-retrospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.99998","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}